You may also like
Hemoadsorption Eliminates Remdesivir from the Circulation: Implications for the Treatment Of COVID-19
Remdesivir and its main active metabolite GS‐441524 are rapidly eliminated from the perfusate by the CytoSorb® adsorber device in vitro. This should be considered in patients for whom both therapies are indicated, and simultaneous application should be avoided. In general, plasma levels of therapeutic drugs should be closely monitored under concurrent CytoSorb® therapy.
1 min read
Bivalirudin Anticoagulation During Cardiac Surgery: A Single-Center Experience in 141 Patients
Here, we report our single-center experience with bivalirudin anticoagulation in "on-pump" and "off-pump" cardiac surgery in a large number of patients with and without heparin antibodies.
1 min read
Left Ventricular Assist Device Performance With Long-Term Circulatory Support: Lessons From the REMATCH Trial
Despite the observed rates of device malfunction and replacement, LVAD implantation confers clinically significant improvement with regard to survival as compared with medical management.
1 min read